Analysis of patients' narratives posted on social media websites on benfluorex's (Mediator®) withdrawal in France

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 1, 2014, Pages 53-55

  Abou Taam, M ^a   Rossard, C ^a   Cantaloube, L ^a   Bouscaren, N ^a   Roche, G ^a   Pochard, L ^a   Montastruc, F ^a   Herxheimer, A ^b   Montastruc, J L ^a   Bagheri, H ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b UK COCHRANE CENTRE   (United Kingdom)

Author keywords

adverse drug reactions; Cybervigilance; drug withdrawal

Indexed keywords

'MEDIATOR'; BENFLUOREX; UNCLASSIFIED DRUG;

ANGER; ANXIETY; ARTICLE; CARDIOVASCULAR DISEASE; CONSUMER ATTITUDE; DIARRHEA; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFORMATION; DRUG WITHDRAWAL; FRANCE; HEALTH CARE SYSTEM; HUMAN; INFORMATION DISSEMINATION; INTERNET; ONLINE SYSTEM; PERCEPTION; SOCIAL MEDIA; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

ADVERSE DRUG REACTIONS; CYBERVIGILANCE; DRUG WITHDRAWAL;

ADVERSE DRUG REACTION REPORTING SYSTEMS; COMMUNICATION; FEMALE; FENFLURAMINE; FRANCE; HUMANS; INTERNET; MIDDLE AGED; SAFETY-BASED DRUG WITHDRAWALS; SOCIAL MEDIA;

EID: 84891835830     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12103     Document Type: Article

References (12)

1. Eaton I,. Europeans and Americans turn to internet for health information. Br Med J, 2002; 325: 989.
2. Herxheimer A, McPherson A, Miller R, Shepperd S, Yaphe J, Ziebland S,. A database of patients' experiences (DIPEx): new ways of sharing experiences and information using a multi-media approach. Lancet, 2000; 355: 1540-1543.
3. Schröder S, Zöller YF, Schaefer M,. Drug related problems with antiparkinsonian agents: consumer Internet reports versus published data. Pharmacoepidemiol Drug Saf, 2007; 16: 1161-1166.
4. Hughes S, Cohen D,. Can online consumers contribute to drug knowledge? A mixed-methods comparison of consumer-generated and professionally controlled psychotropic medication information on the internet. J Med Internet Res, 2011; 13: e53.
5. Butt TF, Cox AR, Lewis H, Ferner RE,. Patient experiences of serious adverse drug reactions and their attitudes to medicines: a qualitative study of survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. Drug Saf, 2011; 34: 319-328.
6. Dusetzina SB, Higashi AS, Dorsey ER, et al,. Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Med Care, 2012; 50: 466-478.
7. Weill A, Païta M, Tuppin P, et al,. Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf, 2010; 19: 1256-1262.
8. Frachon I, Etienne Y, Jobic Y, Legal G, Humbert M, Leroyer C,. Benfluorex and unexplained valvular heart disease: a case-control study. PLoS ONE, 2010; 4: e10128.
9. Fournier A, Zureik M,. Estimate of deaths due to valvular insufficiency attributable to the use of benfluorex in France. Pharmacoepidemiol Drug Saf, 2012; 21: 343-351.
10. Benkimoun P,. Appetite suppressant was probably responsible for 1300 deaths, study shows. Br Med J, 2012; 344: e996.
11. Ziebland S, Herxheimer A,. How patients' experiences contribute to decision making: illustrations from DIPEx. J Nurs Manag, 2008; 4: 433-439.
12. Edwards IR,. Pharmacovigilance. Br J Clin Pharmacol, 2012; 73: 979-982.